7 Hills Pharma Receives Groundbreaking ‘Patent Estate’ That Covers Integrin Activators to Enhance Efficacy of Immunotherapies
The subsequent faulty cell adhesion contributes to the reason that flu vaccines are not protecting more than half of people more than 65 years old.
Clinical-stage immunotherapy firm, 7 Hills Pharma announced earlier today, it has been awarded broad patent protection from the United States Patent and Trademark Office or USPTO on four patents that cover the use of the firm's integrin activators with any healing antibody, barrier inhibitor for immuno-oncology, and any vaccine.
According to 7HP President and CEO Upendra Marathi, PhD., MBA, such patents' issuance specifies that the USPTO acknowledged the integrins' primary role, as well as the distinctive functionality "of our integrin activators in allowing such board claims."
Upendra, also the technology's co-inventor added, that the said patent coverage "on the integrin-based immunomodulatory platform technology" may allow the pharma company to be positioned as a vital partner for developers of vaccines and immuno-oncology.
Promoting Cell Adhesion
Essentially, the oral small molecule integrin activators of 7HP directly promote "cell adhesion," which is vital for the activation of the immune system, not to mention, for the strengthening of antigen particular immune reactions of immunotherapies like "checkpoint inhibitors for solid tumor cancers," as well as flu and COVID-19 vaccines.
Preclinical data specify, too, a "positive safety profile" for the immunostimulants of this immunotherapy company.
In the immunosuppressive setting of a lot of solid tumors and older people, the "counter ligands for the integrin receptors" are frequently said to be down-regulated, thus, negotiating proper trafficking and stimulation of the immune system.
The subsequent faulty cell adhesion contributes to the reason that flu vaccines are not protecting more than half of people more than 65 years old. The idea is that immune-oncology medications do not succeed in 70 percent of cancer patients.
DON'T MISS THIS: Britain Wins Rare Compliment for Its Leadership in the Race for Life-Saving COVID-19 Drug Test
7HP's Aim to Enhance Efficiency
The compounds of 7HP aim to enhance the efficiency of such therapies and considerably augment the number of patients benefiting from them.
Furthermore, technology was co-invented by 7HP researchers and the Texas Heart Institute. Specifically, co-inventor and Vice President for Research at Texas Heart Institute, Darren Woodside, Ph.D. Said, integrins, specifically, "α4β1 and αLβ2" are vital for engineering "productive antigen-specific immune reactions."
Through the enhancement of integrin's role, Woodside explained this method signifies an innovative tactic to improve immune receptiveness to therapies for cancer and vaccine.
7HP's "issued patent number 10,342,866" covers any of the integrin activator's composition claims, not to mention any therapeutic antibodies.
Moreover, the firm's patent number 10,709,781 issued by 7HP, covers any of the integrin activator's composition claims and any of the "immune checkpoint inhibitors."
Meanwhile, patent numbers 10,709,780 and 10,716,849 cover any vaccine's composition claims. Such claims include the new integrin activators, as well as the antigen and method claims for the administration of vaccine compositions, respectively.
The US Food and Drug Administration or FDA has certified the application of Investigational New Drug or IND of 7HP for its lead integrin activator, specifically, the 7HP349, for administration with "immune-oncology medications, and influenza and COVID-19 vaccines. Relatively, the firm is expecting Phase 1 trials to start in the fall this year.
The 7HP
7 Hills Pharma is a company known for developing innovative, cost-effective, and available "immunomodulatory agents," controlling a popularly known "integrin biology" to initiate or motivate and improve the vital steps in the immune cycle.
Notably, the lead programs of this firm strive to enhance the efficacy of immuno-oncology therapies, including vaccines and checkpoint inhibitors, transplantation of cord blood in terms of treating cancers, and genetic diseases.
IN CASE YOU MISSED THIS: Kodak Branches Out With New Pharmaceutical Business Backed by the US Government
Aug 05, 2020 06:20 AM EDT
